DUBLIN–(BUSINESS WIRE)–The “Lupus Nephritis (LN) – Market Insights, Epidemiology and Market Forecast to 2028” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of LN in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Lupus Nephritis (LN) from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Lupus Nephritis Epidemiology
The total number of prevalent cases of Lupus Nephritis (LN) in 7 MM was found to be 190,819 in the year 2017.
The Lupus Nephritis (LN) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, gender-specific prevalent cases, class-specific prevalent cases, clinical manifestations and diagnosed cases of LN) scenario of Lupus Nephritis (LN) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.
Lupus Nephritis Drug Chapters
This segment of the Lupus Nephritis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The market forecast solely focuses on the market revenue generated by the pharmacological treatment. The mainstays for addressing LN are mainly dominated with Glucocorticosteroids (Prednisone or methylprednisolone); Immunosuppressants (Cyclophosphamide, Azathioprine, Mycophenolate mofetil (MMF); Others (Monoclonal antibodies, such as Rituximab) and Adjunctive Therapies (such as Hydroxychloroquine, Angiotensin-converting enzyme (ACE) inhibitor, angiotensin receptor blockers, etc.).
Among these treatment options, immunosuppressants and corticosteroids are being prescribed as an initial line treatment, which is further followed by Rituxan as a last resort (Second Line) pharmacological option in the advanced stage of the disease. Detailed chapter for upcoming therapies like Obinutuzumab (Roche), Voclosporin (Aurinia Pharmaceuticals) and many others have been covered in the report.
Lupus Nephritis Market Outlook
The market of Lupus Nephritis in 7MM was found to be USD 1,360 million in 2017, and is expected to increase from 2017-2028.
The Lupus Nephritis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Lupus Nephritis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Lupus Nephritis Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Lupus Nephritis Report Key Strengths
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
Lupus Nephritis Report Assessment
- Current Treatment Practices
- Unmet Needs
- Detailed Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
Key Benefits
- This report will help to develop Business Strategies by understanding the trends shaping and driving Lupus Nephritis market
- Organize sales and marketing efforts by identifying the best opportunities for Lupus Nephritis market
- To understand the future market competition in the Lupus Nephritis market.
Companies Mentioned
- Astellas Pharma
- Roche
- GlaxoSmithKline
- Aurinia Pharmaceuticals
- AstraZeneca
- Boehringer Ingelheim
- Novartis
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/jrpp8h
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900